Defining palliative opportunities in pediatric patients with bone and soft tissue sarcomas. Issue 10 (24th July 2020)

• Record Type: Journal Article
• Authors: Ebelhar, Jonathan; Allen, Kristen; DeGroote, Nicholas; Wasilewski‐Masker, Karen; Brock, Katharine E.
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 10(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-24
• Subjects: end‐of‐life care -- oncology -- palliative opportunity -- pediatric palliative care -- soft tissue sarcoma -- solid tumor -- supportive care; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28363
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Pediatric patients with sarcomas experience significant morbidity and compromised quality of life throughout their course. These times could be viewed as opportunities for increased subspecialty palliative care (PC). Systematically defining opportunities for additional PC support has not occurred in pediatric oncology. The frequency, timing, and associated factors for palliative opportunities in pediatric patients with sarcomas are unknown. Methods: A priori, nine palliative opportunities were defined (disease progression or relapse, admission for symptoms, social concerns or end‐of‐life, intensive care or bone marrow transplant admission, phase 1 trial or hospice enrollment, do‐not‐resuscitate status). A single‐center retrospective review was conducted on patients aged 0‐18 years with bone/soft tissue sarcomas who died from January 1, 2012 to November 30, 2017. Demographic, disease, and treatment data were collected. Descriptive statistics were performed. Opportunities were evaluated over quartiles from diagnosis to death. Results: Patients (n = 60) had a mean of nine (SD = 4) palliative opportunities with the majority occurring in the last quartile of the disease course. Number and type of opportunities did not differ by demographics or diagnosis. Eighteen patients (30%) received PC consultation a median of 2.2 months (interquartile range [IQR] 11.5) prior to death. Consultation was unrelated to diagnosis or total opportunities. Conclusions: Patients with sarcomas incur repeated events warranting subspecialty PC, which increase toward the end‐of‐life. Increased PC utilization may help decrease suffering and bolster family coping during these episodes. Additional work should further refine if opportunities differ across cancers, and how to incorporate this framework into clinical oncology care to prevent missed opportunities for PC.